RA Capital Management — Science Meets Wall Street

RA Capital Management is a crossover life sciences investment firm that bridges the gap between private venture investing and public markets. Founded by Peter Kolchinsky, a virologist-turned-investor, the firm manages over $10 billion and is known for its rigorous, science-first approach to biotech investing.

Key Facts

Investment Philosophy

RA Capital's approach is defined by the crossover model:

• Private investments — funding biotech companies pre-IPO, often participating in Series A/B rounds
• Public markets — continuing to invest post-IPO, providing capital at multiple stages
• Science-first — every investment decision starts with the science. The team evaluates drug mechanisms, clinical trial design, and probability of success
• Engaged investing — often takes board seats and helps shape company strategy
• Flexible capital — can invest across the company lifecycle, unlike pure VCs or public-only funds

Key People

• Peter Kolchinsky, PhD — Founder and Managing Partner. Virologist by training (PhD from Harvard). Author of "The Great American Drug Deal." Thought leader on drug pricing and biotech innovation.
• Rajeev Shah — Managing Partner. Drives investment strategy alongside Kolchinsky.

Portfolio Approach

Why Track RA Capital?

RA Capital sees companies before the public market does. As a crossover investor, they invest privately and then continue to hold through IPOs — their presence in an IPO is often a strong signal of scientific conviction.

What you can learn:

• Crossover advantage — seeing companies early gives information edge
• Science matters — RA Capital's PhD-heavy team represents the gold standard of biotech analysis
• Drug pricing matters — Kolchinsky's work on drug economics provides macro insight

Track RA Capital's public positions with Freenance to see which biotech companies have the backing of one of the most scientifically rigorous firms in the business.

Try Freenance for free →

FAQ

What is a crossover fund?

A crossover fund invests in both private (pre-IPO) and public companies. RA Capital invests in biotech companies early in their lifecycle and often continues to hold shares after the company goes public, providing continuity of support.

Who is Peter Kolchinsky?

Peter Kolchinsky is the founder of RA Capital and a trained virologist (Harvard PhD). He's also a public intellectual — his book "The Great American Drug Deal" addresses drug pricing and innovation. He's one of the most respected voices in biotech.

How does RA Capital evaluate biotech investments?

RA Capital evaluates investments through rigorous scientific analysis — examining drug mechanisms, clinical trial design, therapeutic area dynamics, and probability of regulatory approval. The team includes numerous PhDs and MDs who review data at the molecular level.